Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Tuesday, March 19, 2024 | Back issues
Courthouse News Service Courthouse News Service

Pharma Merger

WILMINGTON, Del. - Directors are selling Ambit Biosciences too cheaply through an unfair process to Daiichi Sankyo, for $15 a share or $410 million, shareholders claim in a class action in Chancery Court.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...